Identification of 3 key genes as novel diagnostic and therapeutic targets for OA and COVID-19

Abstract

BackgroundCorona Virus Disease 2019 (COVID-19) and Osteoarthritis (OA) are diseases that seriously affect the physical and mental health and life quality of patients, particularly elderly patients. However, the association between COVID-19 and osteoarthritis at the genetic level has not been investigated. This study is intended to analyze the pathogenesis shared by OA and COVID-19 and to identify drugs that could be used to treat SARS-CoV-2-infected OA patients.MethodsThe four datasets of OA and COVID-19 (GSE114007, GSE55235, GSE147507, and GSE17111) used for the analysis in this paper were obtained from the GEO database. Common genes of OA and COVID-19 were identified through Weighted Gene Co-Expression Network Analysis (WGCNA) and differential gene expression analysis. The least absolute shrinkage and selection operator (LASSO) algorithm was used to screen key genes, which were analyzed for expression patterns by single-cell analysis. Finally, drug prediction and molecular docking were carried out using the Drug Signatures Database (DSigDB) and AutoDockToolsResultsFirstly, WGCNA identified a total of 26 genes common between OA and COVID-19, and functional analysis of the common genes revealed the common pathological processes and molecular changes between OA and COVID-19 are mainly related to immune dysfunction. In addition, we screened 3 key genes, DDIT3, MAFF, and PNRC1, and uncovered that key genes are possibly involved in the pathogenesis of OA and COVID-19 through high expression in neutrophils. Finally, we established a regulatory network of common genes between OA and COVID-19, and the free energy of binding estimation was used to identify suitable medicines for the treatment of OA patients infected with SARS-CoV-2.ConclusionIn the present study, we succeeded in identifying 3 key genes, DDIT3, MAFF, and PNRC1, which are possibly involved in the development of both OA and COVID-19 and have high diagnostic value for OA and COVID-19. In addition, niclosamide, ciclopirox, and ticlopidine were found to be potentially useful for the treatment of OA patients infected with SARS-CoV-2.

Exploration of the link between COVID-19 and gastric cancer from the perspective of bioinformatics and systems biology

“…Ciclopirox regulates the growth and autophagic cell death of GC cells by regulating the phosphorylation of STAT3 at Tyr705 and Ser727 residues, and suggests that ciclopirox may be a potential treatment for GC [75]. Consistent with this study, Zhang et al identified ciclopirox as a potential therapeutic agent for the treatment of patients with SARS-CoV-2 infection through drug prediction and simulated docking patterns [76]. Resveratrol is considered an anti-inflammatory and antiviral agent.…”

Investigation of the relationship between COVID-19 and pancreatic cancer using bioinformatics and systems biology approaches

“…The antifungal drug ciclopirox ethanolamine has been reported to be superior to gemcitabine in a pancreatic cancer model. [ 82 ] In line with this research, Zhang et al [ 83 ] identified ciclopirox as a potential therapeutic agent for treating patients with SARS-CoV-2 infection using drug prediction and simulated docking patterns. Dasatinib can enhance the inhibitory activity of paclitaxel and gemcitabine on human pancreatic cancer cells.…”

Identification of shared pathogenetic mechanisms between COVID-19 and IC through bioinformatics and system biology

“…Since the emergence of the COVID-19 pandemic in 2019, global confirmed cases have exceeded 700 million, leading to intricate complications that strain patient diagnosis and treatment 38 . The typical clinical symptoms of this disease include fever, dry cough, and fatigue, along with chills, headaches, sore throats, shortness of breath, and difficulty breathing 39 .…”